- MacRumors, Friday, September 18, 2009 1:37 PM
So, it looks like Google has released an unredacted copy of its response to an investigation by the U.S. Federal Communications Commission into Apple's apparent rejection of the company's Google Voice
iPhone application. Notably, Google's filing seemingly claims that Apple SVP Phil Schiller personally informed Google that the Google Voice iPhone application had been rejected because it "duplicated
the core dialer functionality of the iPhone."
The claim directly contradicts Apple's response to the FCC, which asserted that the Google Voice application had not been rejected and was
still being studied. How will the FCC proceed? Have the two hug it out and make friends, we hope.
Read the whole story at MacRumors »
My projects Google rejected .
May be this projects will be interesting for my friends in Yahoo.
Sergey Serdyuk
1. "method for potentiating drugs"
Electrical vagus stimulation is considered as the most effective method of treatment of such diseases as epilepsy, depression, chronic pain, drug addiction, obesity, resisted to action of drugs. However the mentioned method demands expensive operation and is not safe (it can cause cardiac arrest, bronchospasm, abdominal pains and other complications.). I suggest safe method of the chemical stimulation of the receptors of vagal afferents by agonists of peripheral receptors: cholecystokinin (CCK), glutamate, ??P, epinephrine, phenylephrine, carbacholine and adenosine, weakly penetrating into CNS, which in small, not causing side-effects doses after systemic or oral administration selectively stimulate chemoceptors of vagal afferents. Chemical stimulation of vagal afferents by agonists of peripheral receptors eliminates pain, depression, anxiety, convulsions, hypoxia, inflammation, neurodegeneration, psychosis,extrapyramidal disorder , stress disorder, that the most important thing, in tens and hundreds times potentiates action of analgesics, antidepressants, antiepileptics, neuroleptics, antiparkinsonian drugs, neuroprotective drugs, antihypoxic agent, stress protective agents without increasing of side- effects of drugs (US patent 6.833.377, US patent application 20050192220). In contrast to expensive and unsafe method of the electrical vagus stimulation the offered method of chemical vagus stimulation is safe, cheap and accessible to patients as allows to use agonists of peripheral receptors in the standard dosage form (solutions, tablets, syrups, granules) or can be added to dosage form of known drugs. The method does not have any disadvantages, except one - he is not necessary to known pharmaceutical companies as decreases of doses of drugs and, in addition, substitution of these drugs to cheap stimulators of vagal afferents (which any patient can independently use) may cause to drop in profit of pharmaceutical firms. The idea can be realised quickly enough, for two years term because the used substances are allowed to clinical application. As a whole, the idea is devoted to the problem of creating of the simple and accessible method of chemical stimulation of vagus for the purpose of mass treatment of many diseases, and also potentiation of effects of analgesics, antidepressants, neuroleptics, antiepileptics, antiparkinsonian drugs, neuroprotective drugs, anti-inflammatory drugs, antihypoxics agent, stress protective agents without side-effects and complications. Realisation of the idea will allow to reduce considerably doses and to eliminate side-effects of known drugs, and in the long term - to substitute these drugs with much cheaper chemical stimulators of vagal afferents which any patient can independently use without limitation. Means are necessary for carrying out of the preclinical researches in animal models of pain, depression, epilepsy, parkinsonism, hypoxia, anxiety, psychosis, neurodegeneration, inflammation and also for carrying out of toxicological researches in animals. At the second stage it is supposed to estimate safety of the method on volunteers and to spend 1 stage of clinical trials. Successful completion of preclinical and clinical experiments will allow to suggest simple and accessible method of chemical stimulation of vagus for treatment of many illnesses, and also method of potentiation of effect of analgetics, antidepressants, neuroleptics, antiepileptics, antiparkinsonian drugs, anti-inflammatory drugs, neuroprotective drugs, antihypoxic agent, stress protective agents without side-effects and complications. The references: 1) Patent US 6,833,377. S. Serdyuk, Composition and method for potentiating drugs. 2) Patent Application Publication Pub. No.0192220. S. Serdyuk, Composition and method for potentiating drugs. 3) Serdyuk S.E., Gmiro V.E., Epinephrine potentiates the analgesic and antidepressant effects of polyvinylpyrrolidone and cholecystokinin due to stimulation of afferents in the gastric mucosa. Bull. Exp. Biol. Med. 2007, 143(3): 350-352. 4) Gmiro V.E., Serdyuk S.E. Epinephrine potentiates antipsychotic, but not cataleptogenic effect of haloperidol in rats. Bull. Exp. Biol. Med. 2007, 143(5): 617-619. 5) Gmiro V.E., Serdyuk S.E. Epinephrine potentiates antipsychotic, but not cataleptogenic effect of haloperidol in rats. Bull. Exp. Biol. Med. 2007, 143(5): 617-619.
2. "The method stimulation of vagal afferents for treatment of pain and potentiation of analgesic action of opiates without development of tolerance and drug addiction . I suggest original and safe method of selective chemical stimulation of subdiaphragmatic vagal afferents for treatment of pain and potentiation of analgesic action of opiates without development of tolerance and drug addiction. The method consists in systemic or oral administration of agonists of peripheral receptors: cholecystokinin (CCK), glutamate, ??P, adrenaline and adenosine, weakly penetrating into CNS, in small, not causing side-effect doses. It is known, that the maximum analgesic action of opiates occurs only in the high doses causing numerous side-effects and complications, including development of tolerance and addiction to opiates. I suggest the original and safe method of selective chemical stimulation of the subdiaphragmatic vagal afferents, designed for treatment of pain and potentiation of effect of low doses of opiates without development of tolerance and addiction to opiates. Stimulation of vagal afferents is achieved by systemic or oral administration of agonists of peripheral receptors: cholecystokinin (CCK), glutamate, ??P, adrenaline and adenosine, weakly penetrating into CNS in small, not causing side-effects doses (US patent application 20050192220). The above-mentioned method can be used also for elimination of side-effects and complications of the maximal possible doses of opiates, including development of tolerance and addiction to opiates. The idea can be realised quickly enough, for two years term because the used substances are allowed to clinical application. The method does not any disadvantages, except one - it is not necessary to known pharmaceutical companies as decrease of doses of drugs and especially changing of these drugs by stimulators of vagal afferents (which any patient can independently use) will lead to elimination of tolerance and addiction to opiates and consequently, to catastrophic falling of demand for narcotic analgetics and narcotics.As a whole, the idea is devoted to the problem of creating of the simple and accessible method of chemical stimulation of vagus for mass treatment of acute and chronic pain, without development of tolerance and drug addiction. The offered method can be used not only for potentiation of analgesic action of morphine and other opiates in small doses, but also for elimination of their side-effects and complications in case of using of narcotic analgesics in maximal possible doses.Realisation of the idea will allow to reduce considerably doses and to eliminate side-effects of known narcotic analgesics , and in the long term to change opiates with much cheaper chemical stimulators of vagal afferents which any patient can independently use without limitation. Means are necessary for carrying out of the preclinical researches in animal models of acute and chronic pain ,hyperalgesia ,tolerarance and addiction to opiates , and also for carrying out of toxicological researches in animals. At the second stage it is supposed to estimate safety of the method on volunteers and to spend 1 stage of clinical trialsSuccessful completion of preclinical and clinical experiments will allow to suggest simple and accessible method of chemical stimulation of vagus for treatment of acute and chronic pain ,hyperalgesia , tolerance and addiction to opiates , and also method of potentiation of analgesic effect of opiates in small doses without side-effects and complications. The above-mentioned method can be used also for elimination of side-effects and complications of the maximal possible doses of opiates, including development of tolerance and addiction to opiates The references: 1) Patent US 6,833,377. S. Serdyuk, Composition and method for potentiating drugs. 2) Patent Application Publication Pub. No.0192220. S. Serdyuk, Composition and method for potentiating drugs. 3) Serdyuk S.E., Gmiro V.E., Epinephrine potentiates the analgesic and antidepressant effects of polyvinylpyrrolidone and cholecystokinin due to stimulation of afferents in the gastric mucosa. Bull. Exp. Biol. Med. 2007, 143(3): 350-352. 4) Gmiro V.E., Serdyuk S.E. Epinephrine potentiates antipsychotic, but not cataleptogenic effect of haloperidol in rats. Bull. Exp. Biol. Med. 2007, 143(5): 617-619. 5) Gmiro V.E., Serdyuk S.E. Epinephrine potentiates antipsychotic, but not cataleptogenic effect of haloperidol in rats. Bull. Exp. Biol. Med. 2007, 143(5): 617-619. _____________________________________________________________